Bitcoin buyers have removed a significant sell wall at around $85,000, reducing resistance and potentially allowing the price to climb higher. This sell wall, a large cluster of sell orders, had previously blocked Bitcoin's advance after a brief spike above $85,000 on September 21, which was partly driven by $648 million in short liquidations. However, demand from US spot Bitcoin ETFs cooled sharply, and long-term holders began taking profits, which kept the price from sustaining above $85,000. Key support levels remain near $73,300 and $77,200, and traders should watch if the sell wall reappears, ETF flows, and long-term holder behavior for clues on Bitcoin's next move.
Bitcoin buyers clearing the $85K sell wall provide context for market conditions. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 02, 2026 00:23 WIB: out of 50 major cryptocurrencies, 14 rose and 35 fell. Notable movers include ATOM at Rp30.952 with a 2.74% decline, GRT at Rp515 down 2.32%, and SNX at Rp4.482 down 2.29%, with strong buy activity on SNX at 93%.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
